Inactive Instrument

Actelion Stock London S.E.

Equities

CH0010532478

Biotechnology & Medical Research

Chart Actelion

Duration

Period

Style

Latest news about Actelion

Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	17-07-31	RE
Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	17-07-18	RE
Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	17-07-18	RE
Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	17-06-09	RE
Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	17-06-09	RE
Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	17-06-09	RE
Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	17-05-22	RE
Actelion : Johnson & Johnson offers EU concessions over Actelion deal	17-05-18	RE
Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	17-04-20	RE
Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	17-04-18	RE
Actelion : shareholders back R&D spinoff, keep J&J deal on track	17-04-05	RE
Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	17-03-31	RE
Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	17-02-22	RE
Bristol Myers Squibb : Icahn buys Bristol-Myers shares, adding to activist pressure	17-02-21	RE
Actelion : How Sanofi lost out to J&J in $30 billion battle for Actelion	17-02-16	RE

Analyst Recommendations on Actelion

Dollar's post-Fed rally pauses, U.S. stocks end lower	16-12-16	RE
Actelion : raises guidance for third time this year on strong PAH sales	16-10-20	RE

More recommendations

Press releases Actelion

Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	20-04-06	AQ
Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	17-10-31	GL
Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	17-06-30	GL
Actelion : Johnson & Johnson Completes Acquisition of Actelion	17-06-16	GL
Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	17-06-15	PU

More press releases

News in other languages on Actelion

Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR	18-01-29
Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR	18-01-29
Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie	18-01-22
GNW-News: Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	17-10-31
Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	17-10-31

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
ARGENX SE	+24.98%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-16.73%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B

Bio Therapeutic Drugs

Protect and grow your investments with the help of our experts

Secure my Investments

fermer